Expert Review of Precision Medicine and Drug Development最新文献

筛选
英文 中文
GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. GUCY2C作为结直肠癌患者靶向精准治疗的生物标志物。
IF 1.2
Expert Review of Precision Medicine and Drug Development Pub Date : 2021-01-01 Epub Date: 2021-02-02 DOI: 10.1080/23808993.2021.1876518
Amanda N Lisby, John C Flickinger, Babar Bashir, Megan Weindorfer, Sanjna Shelukar, Madison Crutcher, Adam E Snook, Scott A Waldman
{"title":"GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer.","authors":"Amanda N Lisby,&nbsp;John C Flickinger,&nbsp;Babar Bashir,&nbsp;Megan Weindorfer,&nbsp;Sanjna Shelukar,&nbsp;Madison Crutcher,&nbsp;Adam E Snook,&nbsp;Scott A Waldman","doi":"10.1080/23808993.2021.1876518","DOIUrl":"https://doi.org/10.1080/23808993.2021.1876518","url":null,"abstract":"<p><strong>Introduction: </strong>Colorectal cancer (CRC) is one of the most-deadly malignancies worldwide. Current therapeutic regimens for CRC patients are relatively generic, based primarily on disease type and stage, with little variation. As the field of molecular oncology advances, so too must therapeutic management of CRC. Understanding molecular heterogeneity has led to a new-found promotion for precision therapy in CRC; underlining the diversity of molecularly targeted therapies based on individual tumor characteristics.</p><p><strong>Areas covered: </strong>We review current approaches for the treatment of CRC and discuss the potential of precision therapy in advanced CRC. We highlight the utility of the intestinal protein guanylyl cyclase C (GUCY2C), as a multi-purpose biomarker and unique therapeutic target in CRC. Here, we summarize current GUCY2C-targeted approaches for treatment of CRC.</p><p><strong>Expert opinion: </strong>The GUCY2C biomarker has multi-faceted utility in medicine. Developmental investment of GUCY2C as a diagnostic and therapeutic biomarker offers a variety of options taking the molecular characteristics of cancer into account. From GUCY2C-targeted therapies, namely cancer vaccines, CAR-T cells, and monoclonal antibodies, to GUCY2C agonists for chemoprevention in those who are at high risk for developing colorectal cancer, the utility of this protein provides many avenues for exploration with significance in the field of precision medicine.</p>","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"6 2","pages":"117-129"},"PeriodicalIF":1.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2021.1876518","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38941879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
The Use of Blood Biomarkers in Precision Medicine for the Primary Prevention of Atherosclerotic Cardiovascular Disease: a Review. 血液生物标志物在精准医学中用于动脉粥样硬化性心血管疾病一级预防的研究进展
IF 1.2
Expert Review of Precision Medicine and Drug Development Pub Date : 2021-01-01 Epub Date: 2021-05-26 DOI: 10.1080/23808993.2021.1930531
Ty Sweeney, Renato Quispe, Thomas Das, Stephen P Juraschek, Seth S Martin, Erin D Michos
{"title":"The Use of Blood Biomarkers in Precision Medicine for the Primary Prevention of Atherosclerotic Cardiovascular Disease: a Review.","authors":"Ty Sweeney,&nbsp;Renato Quispe,&nbsp;Thomas Das,&nbsp;Stephen P Juraschek,&nbsp;Seth S Martin,&nbsp;Erin D Michos","doi":"10.1080/23808993.2021.1930531","DOIUrl":"https://doi.org/10.1080/23808993.2021.1930531","url":null,"abstract":"<p><strong>Introduction: </strong>A biomarker is a substance, structure, or process that indicates the presence of a disease, infection, or environmental exposure. Clinically useful biomarkers are measurable, improve diagnostic or prognostic performance, and ultimately aid clinicians in determining the initiation, duration, or magnitude of therapy.</p><p><strong>Areas covered: </strong>The purpose of this review is to explore the roles of various blood biomarkers of atherosclerotic cardiovascular disease (ASCVD) and how their use may improve the precision with which clinicians can identify, treat, and ultimately prevent ASCVD. Our review will include lipid biomarkers, markers of cardiac injury and wall stress, markers of inflammation, and a few others.</p><p><strong>Expert opinion: </strong>Several biomarkers have recently been highlighted as \"risk-enhancing factors\" in the 2019 American College of Cardiology/American Heart Association Guideline for the Primary Prevention of ASCVD, which can help guide shared decision-making. These included elevated low-density lipoprotein cholesterol, triglycerides, lipoprotein(a), apolipoprotein B, or high-sensitivity C-reactive protein. However, some other biomarkers mentioned in this review are not commonly used despite showing initial promise as prognostic of ASCVD risk, as it is not clear how treatment decisions should be changed after their measurement among asymptomatic individuals. Future studies should focus on whether biomarker-directed management strategies can improve clinical outcomes.</p>","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":" ","pages":"247-258"},"PeriodicalIF":1.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2021.1930531","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39348990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Clinical application of personalized rheumatoid arthritis risk information: Translational epidemiology leading to precision medicine. 个性化类风湿关节炎风险信息的临床应用:转化流行病学引领精准医学。
IF 1.2
Expert Review of Precision Medicine and Drug Development Pub Date : 2021-01-01 Epub Date: 2020-12-14 DOI: 10.1080/23808993.2021.1857237
Jeffrey A Sparks
{"title":"Clinical application of personalized rheumatoid arthritis risk information: Translational epidemiology leading to precision medicine.","authors":"Jeffrey A Sparks","doi":"10.1080/23808993.2021.1857237","DOIUrl":"https://doi.org/10.1080/23808993.2021.1857237","url":null,"abstract":"Over the last few decades, major progress has been made in identifying risk factors for the development of rheumatoid arthritis (RA), a relatively common chronic disease characterized by inflammatory arthritis with complex etiology [1]. These include both nonmodifiable factors, such as demographics and genetics [2], and potentially modifiable factors, such as cigarette smoking and elevated body mass index [3]. Clinicians may wonder how this growing knowledge may someday apply to clinical practice. A traditional view of epidemiology uses risk factors to passively elucidate an overall disease process or identify trends on a population level. In the context of precision medicine, epidemiologic findings may be used to deconstruct disease heterogeneity [4] while informing the development and implementation of personalized interventions [5], or ‘translational epidemiology.’ This article illustrates two recent translational epidemiologic studies in rheumatology that sought to incorporate personalized risk factors into a clinical framework leading us closer toward precision medicine. A number of important clinical risk tools, such as the Framingham Risk Score for cardiovascular disease [6], have been successfully implemented. While these tools have been validated, they may be inaccurate on an individual level [7] or in distinct populations [6] and may have no ability to incorporate novel risk factors or consider interactions between factors [8]. These tools were typically developed for clinicians to help risk-stratify, screen, treat, or prognosticate; they were less oriented toward assisting in diagnosis. While genetic factors are increasingly tested in clinical practice, interpretation is usually not easily integrated with other risk factors. The effects of traditional clinical risk tools on the patient’s willingness to accept interventions, optimizing health behaviors, and psychologic impact have not been the focus. Thus, traditional clinical risk tools are not directly transferable toward a precision medicine framework. A recent randomized controlled trial sought to investigate the effects of a personalized tool for chronic disease risk over one year on motivation to improve health behaviors, knowledge of risk factors, and psychologic impact. The Personalized Risk Estimator for RA (PRE-RA) Family Study developed a comprehensive RA risk tool [9] that personalized RA risk to demographics, family history, genetics (HLA-DRB1 ‘shared epitope,’ the major genetic RA risk factor [10]), biomarkers (two RA-related serum autoantibodies), and four modifiable RA-related risk behaviors (cigarette smoking, sedentary physical activity, low fish intake, and poor dental hygiene) [11]. The web-based PRE-RA risk tool provided personalized results about overall RA risk (using both relative and absolute risk scales) and the components/explanation of risk [11]. The PRERA Family Study randomized 238 unaffected first-degree relatives of RA patients to receive the personalized","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"6 3","pages":"147-149"},"PeriodicalIF":1.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2021.1857237","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39011744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The evolution of patient-specific precision biomarkers to guide personalized heart-transplant care. 患者特异性精确生物标志物的发展,以指导个性化心脏移植护理。
IF 1.2
Expert Review of Precision Medicine and Drug Development Pub Date : 2021-01-01 Epub Date: 2020-10-28 DOI: 10.1080/23808993.2021.1840273
Mario C Deng
{"title":"The evolution of patient-specific precision biomarkers to guide personalized heart-transplant care.","authors":"Mario C Deng","doi":"10.1080/23808993.2021.1840273","DOIUrl":"https://doi.org/10.1080/23808993.2021.1840273","url":null,"abstract":"<p><strong>Introduction: </strong>In parallel to the clinical maturation of heart transplantation over the last 50 years, rejection testing has been revolutionized within the systems biology paradigm triggered by the Human Genome Project.</p><p><strong>Areas covered: </strong>We have co-developed the first FDA-cleared diagnostic and prognostic leukocyte gene expression profiling biomarker test in transplantation medicine that gained international evidence-based medicine guideline acceptance to rule out moderate/severe acute cellular cardiac allograft rejection without invasive endomyocardial biopsies. This work prompted molecular re-classification of intragraft biology, culminating in the identification of a pattern of intragraft myocyte injury, in addition to acute cellular rejection and antibody-mediated rejection. This insight stimulated research into non-invasive detection of myocardial allograft injury. The addition of a donor-organ specific myocardial injury marker based on donor-derived cell-free DNA further strengthens the non-invasive monitoring concept, combining the clinical use of two complementary non-invasive blood-based measures, host immune activity-related risk of acute rejection as well as cardiac allograft injury.</p><p><strong>Expert opinion: </strong>This novel complementary non-invasive heart transplant monitoring strategy based on leukocyte gene expression profiling and donor-derived cell-free DNA that incorporates longitudinal variability measures provides an exciting novel algorithm of heart transplant allograft monitoring. This algorithm's clinical utility will need to be tested in an appropriately designed randomized clinical trial which is in preparation.</p>","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"6 1","pages":"51-63"},"PeriodicalIF":1.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2021.1840273","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25528263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Proteome-based pathology: the next frontier in precision medicine. 基于蛋白质组的病理学:精准医学的下一个前沿。
IF 1.2
Expert Review of Precision Medicine and Drug Development Pub Date : 2021-01-01 DOI: 10.1080/23808993.2021.1854611
Michael H Roehrl, Victor B Roehrl, Julia Y Wang
{"title":"Proteome-based pathology: the next frontier in precision medicine.","authors":"Michael H Roehrl,&nbsp;Victor B Roehrl,&nbsp;Julia Y Wang","doi":"10.1080/23808993.2021.1854611","DOIUrl":"https://doi.org/10.1080/23808993.2021.1854611","url":null,"abstract":"Proteins are the true machines of life. Protein enzymes carry out virtually all complex chemical transformations in living organisms, such as nucleic acid synthesis and replication, posttranslational modifications, carbohydrate and lipid metabolism, hormone biosynthesis, proteolysis, and many more. Proteins provide functional context to cells, tissues, and organisms in the form of receptors, signaling cascades, channels, and transporters. Proteins are also major structural components of the cytoskeleton and extracellular matrices. The pathobiology of virtually all diseases can be understood as the malfunctioning of any one or more of this myriad of actions that proteins perform in a spatially and temporally highly orchestrated manner. By contrast, many diseases, especially cancers, continue to be viewed in a nucleic acid-based genomic and mutation-centric manner, but is this good enough?","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"6 1","pages":"1-4"},"PeriodicalIF":1.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2021.1854611","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25531384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Novel insights into the pathogenesis and treatment of NRAS mutant melanoma. 关于 NRAS 突变黑色素瘤发病机制和治疗的新见解。
IF 1.2
Expert Review of Precision Medicine and Drug Development Pub Date : 2021-01-01 Epub Date: 2021-08-11 DOI: 10.1080/23808993.2021.1938545
Jeffrey Zhao, Carlos Galvez, Kathryn Eby Beckermann, Douglas B Johnson, Jeffrey A Sosman
{"title":"Novel insights into the pathogenesis and treatment of NRAS mutant melanoma.","authors":"Jeffrey Zhao, Carlos Galvez, Kathryn Eby Beckermann, Douglas B Johnson, Jeffrey A Sosman","doi":"10.1080/23808993.2021.1938545","DOIUrl":"10.1080/23808993.2021.1938545","url":null,"abstract":"<p><strong>Introduction: </strong>NRAS was the first mutated oncogene identified in melanoma and is currently the second most common driver mutation in this malignancy. For patients with NRAS<sup>mutant</sup> advanced stage melanoma refractory to immunotherapy or with contraindications to immune-based regimens, there are few therapeutic options including low-efficacy chemotherapy regimens and binimetinib monotherapy. Here, we review recent advances in preclinical studies of molecular targets for NRAS mutant melanoma as well as the failures and successes of early-phase clinical trials. While there are no targeted therapies for NRAS-driven melanoma, there is great promise in approaches combining MEK inhibition with inhibitors of the focal adhesion kinase (FAK), inhibitors of autophagy pathways, and pan-RAF inhibitors.</p><p><strong>Areas covered: </strong>This review surveys new developments in all aspects of disease pathogenesis and potential treatment - including those that have failed, stalled, or progressed through various phases of preclinical and clinical development.</p><p><strong>Expert opinion: </strong>There are no currently approved targeted therapies for BRAF wild-type melanoma patients harboring NRAS driver mutations though an array of agents are in early phase clinical trials. The diverse strategies taken exploit combined MAP kinase signaling blockade with inhibition of cell cycle mediators, inhibition of the autophagy pathway, and alteration of kinases involved in actin cytoskeleton signaling. Future advances of developmental therapeutics into late stage trials may yield new options beyond immunotherapy for patients with advanced stage disease and NRAS mutation status.</p>","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"6 4","pages":"281-294"},"PeriodicalIF":1.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415440/pdf/nihms-1714276.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9349969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Personalizing liver targeted treatments and transplantation for patients with alpha-1 antitrypsin deficiency α-1抗胰蛋白酶缺乏症患者的个性化肝靶向治疗和移植
IF 1.2
Expert Review of Precision Medicine and Drug Development Pub Date : 2020-12-31 DOI: 10.1080/23808993.2021.1862648
A. Pye, S. Khan, T. Whitehouse, A. Turner
{"title":"Personalizing liver targeted treatments and transplantation for patients with alpha-1 antitrypsin deficiency","authors":"A. Pye, S. Khan, T. Whitehouse, A. Turner","doi":"10.1080/23808993.2021.1862648","DOIUrl":"https://doi.org/10.1080/23808993.2021.1862648","url":null,"abstract":"ABSTRACT Introduction: There is currently no specific treatment for liver disease due to alpha-1 antitrypsin deficiency (AATD) other than care applied for other liver diseases including transplantation. This review describes the personalized approaches to liver disease in AATD, and the current stage of development of new therapeutic agents. Areas covered: We review the pathology, presentation and progression of AATD liver disease and the approaches being taken to understand the natural history of the disease to aid future therapeutic advances. Peri- and post-transplant care is described and we highlight the reasons that alternative approaches to avoid the need for liver transplantation are being explored. The role of patient selection for new therapies is addressed as this is likely to be of paramount importance to achieve better outcomes. Expert opinion: Treatments directed at both liver, and lung and liver combined, are now being trialed in patients with AATD. The next 5–10 years may determine a more reliable noninvasive measurement of liver fibrosis, together with predictors of who is most likely to progress and develop cirrhosis. Personalized approaches could optimize when and how to effectively manage an individual with a cost-effective treatment and avoid progression to liver transplantation.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"6 1","pages":"65 - 78"},"PeriodicalIF":1.2,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2021.1862648","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43289188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Givosiran, a novel treatment for acute hepatic porphyrias 吉沃西兰治疗急性肝卟啉的新方法
IF 1.2
Expert Review of Precision Medicine and Drug Development Pub Date : 2020-12-24 DOI: 10.1080/23808993.2021.1838275
Manish Thapar, S. Rudnick, H. Bonkovsky
{"title":"Givosiran, a novel treatment for acute hepatic porphyrias","authors":"Manish Thapar, S. Rudnick, H. Bonkovsky","doi":"10.1080/23808993.2021.1838275","DOIUrl":"https://doi.org/10.1080/23808993.2021.1838275","url":null,"abstract":"ABSTRACT Introduction Acute hepatic porphyrias (AHPs) are a group of rare genetic disorders that affect the enzymes of the heme biosynthetic pathway. Patients have a varied presentation, but attacks of severe abdominal pain are the cardinal feature. Until recently, IV hemin was the only definitive treatment option available. Areas covered We summarize salient features of AHP and the work leading to clinical studies of givosiran and to its approval by the US FDA and the EMA. Givosiran is a novel siRNA therapeutic agent that targets hepatic 5-aminolevulinic acid (ALA) synthase-1, the first and rate limiting enzyme in the heme biosynthetic pathway. It has been effective in decreasing the levels of hepatic ALA synthase-1 mRNA, levels of ALA, which likely is the chief neurotoxin, and the composite attack rates in patients with AHP. The drug can cause elevated liver enzymes, elevations in serum creatinine, and injection site reactions. Single doses, given to asymptomatic persons with AIP who are chronic high excretors of ALA and porphobilinogen, caused decreases in CYP1A2 and CYP2D6 activity, raising concern for drug interactions. Expert opinion Givosiran is expensive; insurance plans are likely to limit its availability to patients with well-documented AHP and frequent and severe acute attacks.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"6 1","pages":"9 - 18"},"PeriodicalIF":1.2,"publicationDate":"2020-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2021.1838275","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43244105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Abiraterone acetate plus prednisone/prednisolone in hormone-sensitive and castration-resistant metastatic prostate cancer 醋酸阿比特龙加泼尼松/泼尼松治疗激素敏感性和去势耐药性转移性前列腺癌症
IF 1.2
Expert Review of Precision Medicine and Drug Development Pub Date : 2020-12-23 DOI: 10.1080/23808993.2021.1863781
J. Gschwend, K. Miller
{"title":"Abiraterone acetate plus prednisone/prednisolone in hormone-sensitive and castration-resistant metastatic prostate cancer","authors":"J. Gschwend, K. Miller","doi":"10.1080/23808993.2021.1863781","DOIUrl":"https://doi.org/10.1080/23808993.2021.1863781","url":null,"abstract":"ABSTRACT Introduction: New-generation hormonal therapies such as abiraterone acetate (AA) in combination with prednisone or prednisolone (AAP) have improved the overall survival (OS) in patients with chemotherapy-pretreated and naïve metastatic castration-resistant prostate cancer (mCRPC). More recently, AAP has demonstrated efficacy in newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and has received expanded approval for this indication. Areas covered: This review is intended to provide a thorough overview of AA as the first-in-class and only currently approved steroid 17α-hydroxylase/C17,20-lyase (CYP17) inhibitor for prostate cancer. To the best of our knowledge, this is the most comprehensive review of AAP that covers all three indications: mCRPC in the pre- and post-chemotherapy setting, and mHSPC. We describe, among other things, the mechanism of action of AA and review data on its efficacy and safety from phase 1, 2 and the pivotal phase 3 clinical trials that support its use in the mentioned approved indications. Expert opinion: AAP has been established over the past 10 years and was added to the WHO list of essential medicines in 2019 through an evidence-based selection process in which quality, safety, efficacy, and cost-effectiveness are key criteria, highlighting its role in the current therapeutic landscape of prostate cancer management.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"6 1","pages":"41 - 49"},"PeriodicalIF":1.2,"publicationDate":"2020-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2021.1863781","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46163826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Durvalumab for the treatment of PD-L1 non-small cell lung cancer 杜伐单抗治疗PD-L1非小细胞肺癌癌症
IF 1.2
Expert Review of Precision Medicine and Drug Development Pub Date : 2020-12-17 DOI: 10.1080/23808993.2021.1855075
T. Naito, H. Shiraishi, Y. Fujiwara
{"title":"Durvalumab for the treatment of PD-L1 non-small cell lung cancer","authors":"T. Naito, H. Shiraishi, Y. Fujiwara","doi":"10.1080/23808993.2021.1855075","DOIUrl":"https://doi.org/10.1080/23808993.2021.1855075","url":null,"abstract":"ABSTRACT Introduction: Immune checkpoint inhibitors, monoclonal antibodies directed against programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1), have broadened treatment options for patients with non-small cell lung cancer (NSCLC). Durvalumab is a selective, high-affinity, human IgG1 monoclonal anti-PD-L1 antibody that blocks interactions of PD-L1 with PD-1 and CD80. Areas covered: We reviewed clinical data supporting the use of durvalumab as a monotherapy and combination therapy for the treatment of locally advanced and advanced NSCLC. Expert commentary: Durvalumab as a monotherapy or combination therapy has shown well-tolerated safety profiles for NSCLC in several trials. Durvalumab monotherapy in advanced NSCLC patients with PD-L1 ≥ 25% as later line (ATLANTIC study) therapy led to clinically meaningful improvements compared to standard of care. Combination therapy comprising durvalumab plus tremelimumab for advanced NSCLC did not show clinical efficacy in three phase III trials. Durvalumab administered after chemoradiotherapy in stage III NSCLC (PACIFIC study) significantly improved progression-free survival and overall survival. This result has led to approval of durvalumab for patients with locally advanced NSCLC as the standard of care. Ongoing trials provide insight into how durvalumab fits into the rapidly evolving therapeutic landscape for locally advanced or advanced NSCLC.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"6 1","pages":"95 - 105"},"PeriodicalIF":1.2,"publicationDate":"2020-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2021.1855075","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47734184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信